Corrigendum to "Nanoparticle and targeted systems for cancer therapy" [Advanced Drug Delivery Reviews 56(2004)1649-1659] (DOI:10.1016/j.addr.2004.02.014);Nanoparticle and targeted systems for cancer therapy

Advanced Drug Delivery Reviews

Volumn 56, Issue 11, 2004, Pages 1649-1659

  Brannon Peppas, Lisa ^a   Blanchette, James O ^a  

^a The University of Texas at Austin   (United States)

Author keywords

Angiogenesis; Antibodies; Cancer therapy; Nanoparticles; Targeted delivery

Indexed keywords

ANTIBODIES; BIODEGRADATION; CELLS; MECHANICAL PERMEABILITY; NANOSTRUCTURED MATERIALS; POLYMERS; TUMORS;

ANGIOGENESIS; ANTI-CANCER AGENTS;

CONTROLLED DRUG DELIVERY;

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALEMTUZUMAB; ANGIOSTATIN; ANGIOZYME; ANTINEOPLASTIC AGENT; BENFLURALIN; CC 7085; CDC 801; CILENGITIDE; CM 101; COMBRETASTATIN A4; DOXORUBICIN; ENDOSTATIN; FCE 26644; FLAVOPIRIDOL; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GENISTEIN; IBRITUMOMAB TIUXETAN; IM 862; IRINOTECAN; LENALIDOMIDE; MIDOSTAURIN; NANOPARTICLE; PACLITAXEL; PRINOMASTAT; PRODRUG; REBIMASTAT; RECOMBINANT DNA; RITUXIMAB; RO 317453; SURAMIN; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CELL MEMBRANE PERMEABILITY; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIVER CARCINOMA; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; NONHODGKIN LYMPHOMA; PARTICLE SIZE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; STEADY STATE; TARGET CELL DESTRUCTION; TUMOR VASCULARIZATION;

EID: 4444379133     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.02.001     Document Type: Erratum

References (43)

1. Feng S.-S., Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science. 58:2003;4087-4114
2. Grossfeld G.D., Carrol P.R., Lindeman N. Thrombospondin-1 expression in patients with pathologic state T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis and tumor progression. Urology. 59:2002;97-102
3. Jones A., Harris A.L. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer Journal from Scientific American. 4:1998;209-217
4. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews. 54:2002;631-651
5. Gaur U., Sahoo S.K., De T.K., Ghosh P.C., Maitra A., Ghosh P.K. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. International Journal of Pharmaceutics. 202:2000;1-10
6. Storm G., Belliot S.O., Daemen T., Lasic D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews. 17:1995;31-48
7. Jain R.K. Transport of molecules, particles and cells in solid tumors. Annual Review of Biomedical Engineering. 1:1999;241-263
8. Sledge G., Miller K. Exploiting the hallmarks of cancer: the future conquest of breast cancer. European Journal of Cancer. 39:2003;1668-1675
9. Teicher B.A. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resistance Updates. 3:2000;67-73
10. Chari R.V.J. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Advanced Drug Delivery Reviews. 31:1998;89-104
11. Suzawa T., Nagamura S., Saito H., Ohta S., Hanai N., Kanazawa J., Okabe M., Yamasaki M. Enhanced tumor cell selectivity of adriamycin-monoclonal antobody conjugate via a poly(ethylene-glycol)-based cleavable linker. Journal of Controlled Release. 79:2002;229-242
12. Kohler G., Milstein C. Continuous cultures of fuse cells secreting antibody of predefined specificity. Nature. 75(Suppl. 1):1975;381-394
13. Abou-Jawde R., Choueiri T., Alemany C., Mekhail T. An overview of targeted treatments in cancer. Clinical Therapeutics. 25:2003;2121-2137
14. Glennie M.J., Winkel J.G.J.v.d. Renaissance of cancer therapeutic antibodies. Drug Discovery Today. 8:2003;503-510
15. Hobson B., Denekamp J. Endothelial proliferation in tumors and normal tissues: continuous labeling studies. British Journal of Cancer. 49:1984;405-413
16. Fox S.B., Gatter K.C., Bicknell R. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Research. 53:1993;4161-4163
17. Sepp N., Fritsch P., Luger T.A. Endothelial cells and angiogenesis. Experimental Dermatology. 6:1997;272-273
18. Ingber D.E. Fibronectin controls capillary endothelial cells growth by modulating cell shape. Proceedings of the National Academy of Sciences. 87:1990;3579-3583
19. Eatock M.M., Schätzlain A., Kaye S.B. Tumor vasculature as a target for anticancer therapy. Cancer Treatment Reviews. 26:2000;191-204
20. Chen Q.-R., Zhang L., Gasper W., Mixson A.J. Targeting tumor angiogenesis with gene therapy. Molecular Genetics and Metabolism. 74:2001;120-127
21. Reynolds A.R., Moghimi S.M., Hodivala-Dilke K. Nanoparticle-mediated gene delivery to tumor vasculature. Trends in Molecular Medicine. 9:2003;2-4
22. Folkman J. Successful treatment of an angiogenic disease. New England Journal of Medicine. 320:1989;1211-1212
23. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2002;2404-2407
24. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. International Journal of Pharmaceutics. 235:2002;179-192
25. Wang Y.M., Sato H., Dachi I., Horikoshi I. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of novel anticancer agent, taxol. Chemical and Pharmaceutical Bulletin. 44:1996;1935-1940
26. Si-Shen F., Guofeng H. Effect of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymer. Journal of Controlled Release. 71:2001;53-69
27. Fonseca C., Simões S., Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, phsiochemical characterization and in vitro anti-tumoral activity. Journal of Controlled Release. 83:2002;273-286
28. Mu L., Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (taxol): PLGA nanoparticles containing vitamin E TPGS. Journal of Controlled Release. 86:2003;33-48
29. Yoo H.S., Park T.G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. Polymer Preparation. 41:2000;992-993
30. Mitra S., Gaur U., Ghosh P.C., Maitra A.N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. Journal of Controlled Release. 74:2001;317-323
31. Shikata F., Tokumitsu H., Ichikawa H., Fukumori Y. In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. European Journal of Pharmaceutics and Biopharmaceutics. 53:2002;57-63
32. Bhadra D., Bhadra S., Jain S., Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. International Journal of Pharmaceutics. 257:2003;111-124
33. Williams J., Lansdown R., Sweitzer R., Romanowski M., LaBell R., Ramaswami R., Unger E. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. Journal of Controlled Release. 91:2003;167-172
34. Kircheis R., Kichler A., Wallner G., Kursa M., Ogris M., Felzmann T., Buchberger M., Wagner W. Coupling of cell-binding ligands to polyethylenimine for targeted gene transfer. Gene Therapy. 4:1997;409-418
35. Blessing T., Kursa M., Holzhauser R., Kircheis R., Wagner E. Different strategies for formulation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. Bioconjugate Chemistry. 12:2001;529-537
36. Ogris M., Steinlein P., Carotta S., Brunner S., Wagner E. DNA/polyethylenimine transfection particles: influence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS PharmSciTech. 3:2001;. (article 21)http://www.aapspharmsci.org/view.asp?art=ps030321
37. Ogris M., Walker G., Blessing T., Kircheis R., Wolshek M., Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethyleneimine/DNA complexes. Journal of Controlled Release. 91:2003;173-181
38. Becerril B., Poul M.A., Marks J.D. Toward selection of internalizing antibodies from phage libraries. Biochemical and Biophysical Research Communications. 255:1999;386-393
39. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K., Park J.W., Shalaby M.R., Shao Y., Benz C.C., Marks J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antobody selected for cellular endocytosis. Biochimica et Biophysica Acta. 1591:2002;109-118
40. Kim I.-S., Kim S.-H. Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycvol) with sugar moiety. International Journal of Pharmaceutics. 257:2003;195-203
41. Lu Y., Low P.S. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. Journal of Controlled Release. 91:2003;18-29
42. Rodolfo M., Melani C., Zilocchi C., Cappetti B., Luison E., Arioli I., Parenza M., Canevari S., Colombo M.P. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine associated with the eradication of experimental metastases. Cancer Research. 58:1998;5812-6817
43. Dagar S., Krishnadas A., Rubinstein I., Blend M.J., Önyüksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. Journal of Controlled Release. 91:2003;123-133